111 related articles for article (PubMed ID: 2809219)
1. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation.
Agah R; Malloy B; Kerner M; Mazumder A
J Immunol; 1989 Nov; 143(9):3093-9. PubMed ID: 2809219
[TBL] [Abstract][Full Text] [Related]
2. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice.
Agah R; Malloy B; Kerner M; Girgis E; Bean P; Twomey P; Mazumder A
Cancer Res; 1989 Nov; 49(21):5959-63. PubMed ID: 2790810
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 in bone marrow transplantation: preclinical studies.
Charak BS; Choudhary GD; Tefft M; Mazumder A
Bone Marrow Transplant; 1992 Aug; 10(2):103-11. PubMed ID: 1326364
[TBL] [Abstract][Full Text] [Related]
4. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 (IL-2) and IL-2-activated bone marrow in transplantation: evaluation from a clinical perspective.
Charak BS; Agah R; Brynes RK; Chogyoji M; Groshen S; Chen SC; Mazumder A
Bone Marrow Transplant; 1992 Jun; 9(6):479-86. PubMed ID: 1628133
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
7. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
8. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation.
Tam YK; Klingemann HG
Biol Blood Marrow Transplant; 1999; 5(4):231-42. PubMed ID: 10465103
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
Verma UN; Bagg A; Brown E; Mazumder A
Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
Long GS; Cramer DV; Harnaha JB; Hiserodt JC
Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
[TBL] [Abstract][Full Text] [Related]
11. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer (LAK) cell purging of bone marrow.
Cramer DV; Long GS
Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
[TBL] [Abstract][Full Text] [Related]
13. A novel approach to purging of leukemia by activation of bone marrow with interleukin 2.
Charak BS; Malloy B; Agah R; Mazumder A
Bone Marrow Transplant; 1990 Sep; 6(3):193-8. PubMed ID: 2252959
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to immunomodulation of frozen human bone marrow with interleukin-2 for clinical application.
Charak BS; Areman EM; Dickerson SA; Choudhary GD; Sacher R; Kotula PL; Brown EG; Mazumdar A
Bone Marrow Transplant; 1993 Feb; 11(2):147-54. PubMed ID: 8435664
[TBL] [Abstract][Full Text] [Related]
15. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
16. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
[TBL] [Abstract][Full Text] [Related]
18. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation.
Tam YK; Klingemann HG
Biol Blood Marrow Transplant; 1999; 5(3):144-54. PubMed ID: 10392960
[TBL] [Abstract][Full Text] [Related]
19. Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin 2 therapy.
Charak BS; Brynes RK; Katsuda S; Groshen S; Chen SC; Mazumder A
Cancer Res; 1991 Apr; 51(8):2015-20. PubMed ID: 2009520
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 and syngeneic bone marrow transplantation in a murine fibrosarcoma model.
Ho SP; Stebler B; Ershler WB
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):101-4. PubMed ID: 1873353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
